30S Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Saniona AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.74 |
52 Week High | SEK 0.82 |
52 Week Low | SEK 0.14 |
Beta | 0.80 |
1 Month Change | 39.47% |
3 Month Change | 8.16% |
1 Year Change | 433.81% |
3 Year Change | 233.48% |
5 Year Change | -71.52% |
Change since IPO | -74.61% |
Recent News & Updates
Recent updates
Shareholder Returns
30S | DE Biotechs | DE Market | |
---|---|---|---|
7D | 5.8% | -0.3% | 0.8% |
1Y | 433.8% | -12.7% | 14.6% |
Return vs Industry: 30S exceeded the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 30S exceeded the German Market which returned 14.6% over the past year.
Price Volatility
30S volatility | |
---|---|
30S Average Weekly Movement | 10.9% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 6.6% |
10% most volatile stocks in DE Market | 12.7% |
10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 30S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 30S's weekly volatility has decreased from 23% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 22 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder.
Saniona AB (publ) Fundamentals Summary
30S fundamental statistics | |
---|---|
Market cap | €105.21m |
Earnings (TTM) | €17.29m |
Revenue (TTM) | €30.66m |
6.1x
P/E Ratio3.4x
P/S RatioIs 30S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
30S income statement (TTM) | |
---|---|
Revenue | SEK 334.67m |
Cost of Revenue | SEK 5.10m |
Gross Profit | SEK 329.58m |
Other Expenses | SEK 140.87m |
Earnings | SEK 188.71m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 28, 2025
Earnings per share (EPS) | 1.39 |
Gross Margin | 98.48% |
Net Profit Margin | 56.39% |
Debt/Equity Ratio | 2.3% |
How did 30S perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/18 01:32 |
End of Day Share Price | 2025/05/16 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Saniona AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Michael Novod | Nordea Markets |
Jesper Ilsoe | Nordea Markets |
Fredrik Thor | Redeye |